Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Recruiting
Trial end date:
2023-01-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether potentiating the cystic fibrosis
transmembrane conductance regulator (CFTR) with QBW251 in subjects with COPD will be
efficacious with regards to reducing lung and systemic inflammation and bacterial
colonization as potential drivers of airway obstruction, airway destruction, remodeling and
exacerbations.
Furthermore, this study will provide supportive data to investigate the relationship of COPD
phenotype and the response in small airway structure, function, mucus load and spirometry
indices as well as in improvement of overall COPD symptoms and quality of life.